T-Cell Therapy Market by Type of Therapy (CAR-T, TCR, and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head, and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia

T-Cell Therapy Market by Type of Therapy (CAR-T, TCR, and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head, and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia, and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1, and Others), and Key Geographical Regions (North America, Europe and Asia Pacific, Latin America, Middle East, and North Africa): Industry Trends and Global Forecasts, Till 2035

T-cell Therapy Market: Overview

As per Roots Analysis, the global T-Cell therapy market is estimated to grow from USD 3.5 billion in the current year to USD 33.72 billion by 2035, at a CAGR of 23% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Therapy

• CAR-T
• TCR
• TIL

Target Indication

• Acute Lymphoblastic Leukemia
• Non-Hodgkin’s Lymphoma
• Melanoma
• Bladder Cancer
• Lung Cancer
• Head and Neck Cancer
• Multiple Myeloma
• Sarcoma
• Chronic Lymphocytic Leukemia
• Ovarian Cancer
• Esophageal Cancer
• Colorectal Cancer
• Nasopharyngeal Carcinoma
• Hepatocellular Carcinoma
• Acute Myeloid Leukemia
• Renal Cell Carcinoma

Type of Target Antigens

• CD19
• BCMA
• CD19/22
• EGFR
• NY-ESO-1
• Gp100
• P53
• EBV
• MUC2

Key Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

T-CELL THERAPY MARKET: GROWTH AND TRENDS

Cancer is one of the leading causes of mortality worldwide. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, globally. Despite the fact that cancer therapeutics is one of the most active areas, in terms of drug development, there are several unmet needs in this domain. Moreover, conventional cancer treatments, such as chemotherapy, surgery, and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. In order to cater to the unmet needs of the industry, more initiatives are being taken to develop more targeted anti-cancer therapies, T-cell immunotherapy, specifically CAR-T cell therapies, has emerged as a highly potent option to selectively eliminate the tumor cells with minimal side effects. Immunotherapies essentially make use of body’s own immune system, or its components, to fight against cancer.

Over the past few years, CAR-T therapies have been successful in carving out a significant share of the pharmaceutical market. A number of such targeted therapies have already been approved whilst a robust development pipeline indicates that CAR-T therapies market is likely to grow at a steady pace in the foreseen future. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipelines of the companies in this domain. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results suggest that the CAR-T therapies market is poised to grow in the long run, as multiple product candidates are expected to receive marketing approval in the coming decade.

T-CELL THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the T-Cell therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. With some approved therapies and over 970 preclinical / clinical product candidates, CAR-T cell immunotherapies comprise the most active segment of this domain.

2. More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR cell immunotherapies to treat various oncological and non-oncological disorders.

3. In addition, over 75 TIL immunotherapies are being evaluated across different stages of preclinical / clinical development either as monotherapies or in combination with other drugs.

4. Apart from CAR-T, TCR and TIL-based products, close to 205 other T-cell immunotherapies are marketed / under development for the treatment of a wide range of oncological and non-oncological indications.

5. Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.

6. Across each type of T-cell therapy, at least 80% of the players are developing autologous therapy candidates targeting various disease indications; CD19 and BCMA emerged as the most popular target antigens.

7. A number of scientists from renowned universities are presently involved in clinical development efforts of TCR-based therapies; these KOLs are primarily based in the US and China.

8. Specifically, for CAR-T cell therapies, extensive efforts are underway to improve the CAR constructs across successive generations, involving alterations in the scFv region and using different types of gene delivery vectors.

9. In the last 10 years, over 750 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of therapies.

10. A rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validates the growing interest in this domain.

11. More than 75 patents have been granted / filed for TCR-based therapies, primarily led by the non-industry players.

12. With the growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 20%, during the next decade.

13. The projected opportunity within the T-cell Therapies market is expected to be well distributed across different geographical regions and key / emerging players.

T-CELL THERAPY MARKET: KEY SEGMENTS

CAR-T Therapy is Likely to Dominate the T-Cell Therapy Market During the Forecast Period

Based on the type of therapy, the market is segmented into CAR T cell therapy, TCR therapy, and TIL therapy. At present, CAR-T therapy segment holds the maximum share of the T-Cell therapy market and this trend is likely to remain the same in the coming decade. This can be primally attributed to the proven efficacy of CAR-T therapy in various cancer treatments, such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, myeloid leukemia, and non-Hodgkin’s lymphoma. It is worth highlighting that T-cell therapy market for TCR therapy is likely to grow at a relatively higher CAGR, during the forecast period.

Currently, Non-Hodgkin’s Lymphoma Segment Occupies the Largest Share of the T-Cell Therapy Market

Based on the type of target indications, the market is segmented into acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia and renal cell carcinoma. At present, non-Hodgkin’s lymphoma holds the maximum share of the T-Cell therapy market. This trend is likely to remain the same in the forthcoming years. It is worth highlighting that T-Cell therapy market for sarcoma is likely to grow at a relatively higher CAGR, during the forecast period.

Currently, CD19 Captures the Largest Share of the T-Cell Therapy Market

Based on the type of target antigens, the market is segmented into CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others. At present, the CD19 segment holds the maximum share of the T-Cell therapy market. Owing to its proven efficacy against various types of cancer, such as leukemia and lymphoma, CD19 antigen is anticipated to foster the demand for T-cell therapy over the forecast period.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Majority share is expected to be captured by drug developers based in Europe. It is worth highlighting that rising prevalence various types of cancer, such as hematologic malignancies and solid tumors, and a surge in demand for cancer treatment will drive the growth of the market in Europe.

Example Players in the T-Cell Therapy Market

• Autolus
• Adaptimmune Therapeutics
• Alaunos Therapeutics
• bluebird Bio
• Bristol Myers Squibb
• Carsgen Therapeutics
• Cellectis
• Cellular Biomedicine Group
• Gilead Sciences
• GlaxoSmithKline

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Former Chief Executive Officer, Cell Therapies
• Chief Executive Officer, Glycostem Therapeutics
• Chief Executive Officer, Gracell Biotechnologies
• Co-Founder and Chief Executive Officer, Lion TCR
• Chief Executive Officer, TxCell
• Vice President, Scientific Affairs, Kite Pharma
• Manager of Business Development, Waisman Biomanufacturing
• Vice President (Immuno-Oncology), Celyad
• Former Director, Process Development, Iovance Biotherapeutics
• Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys
• Professor of Medicine and Director, Department of Oncology, Changhai Hospital
• Assistant Professor of Medicine, University of Colorado

T-CELL THERAPY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the T-Cell therapy market, focusing on key market segments, including [A] type of therapy, [B] target indications, [C] target antigens and [D] key geographical regions.
• Market Landscape: A comprehensive evaluation of T-cell immunotherapies, considering various parameters, such as [A] type of developer, [B] phase of development, [C] therapeutic area, [D] key target indication, [E] key target antigen, [F] source of T-cells, [G] route of administration, [H] dose frequency, [I] patient segment, [J] type of therapy and [K] most active industry and non-industry players (in terms of number of pipeline candidates). Additionally, it highlights the developer landscape based on some relevant parameters, including [L] year of establishment, [M] company size and [N] location of headquarters.
• Key Insights: An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation, and fourth generation), type of binding domain (murine, humanized, fully human, and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
• Clinical Trials Analysis: Examination of completed, ongoing, and planned clinical studies of various CAR-Ts, TCRs, and TIL therapies, based on parameters like [A] trial registration year, [B] enrolled patient population, [C] trial recruitment status, [D] trial phase, [E] target patient segment, [F] type of sponsor/collaborator, [G] most active players and [H] regional distribution of trials.
• Key Opinion Leaders (KOLs) Analysis: An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with CAR-Ts, TCRs and TILs therapies. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
• Drug Profiles: In-depth profiles of marketed and mid- to late-stage clinical products (phase I/II or above), focusing on [A] therapy overviews, [B] its mechanism of action, [C] dosage information, [D] details on the cost, [E] sales information (wherever available), [F] clinical development plan, [G] and key clinical trial results.
• Company Profiles: In-depth profiles of key industry players in engaged in the development of T-cell immunotherapies, focusing on [A] product portfolio specific to CAR-T, TCR and TIL therapies, [B] technology portfolio (if available), [C] recent developments related to T-cell immunotherapies, [D] manufacturing capabilities of the companies and [E] details related to the strategic / venture capital investments made in these companies.
• Emerging Technologies: A comprehensive examination of advanced technology platforms utilized in the development of T-cell therapies, including profiles of major technology providers. Additionally, it includes a comparative analysis of various gene editing platforms employed in T-cell therapy development, focusing on several parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
• Funding and Investment Analysis: A detailed evaluation of the investments received by the companies that have proprietary T-cell based products/technologies, encompassing seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
• Patent Analysis: Detailed analysis of various patents filed / granted related to CAR-Ts, TCRs and TILs therapies based on [A] type of patent, [B] publication year, [C] geographical distribution, [D] cooperative patent classification (CPC) symbols, [E] emerging focus areas, [F] type of applicant, [G] leading players (on the basis of number of patents) and [H] patent benchmarking. It also includes a patent benchmarking analysis and a detailed valuation analysis.
• Case Study 1: A case study on other T-cell-based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, featuring information on the current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
• Case Study 2: A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
• Cost Price Analysis: A comprehensive exploration of the various factors that form the pricing of cell-based therapies. This includes an examination of the different models and strategies that pharmaceutical companies may consider when determining the price of T-cell-based immunotherapies that are likely to enter the market in the near future.
• Promotional Analysis: A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older